Ailux Appoints Lloyd S. Miller, M.D., Ph.D., as Chief Medical Officer

October 13, 2026 Dr. Miller will lead the advancement of the company’s AI-native biologics toward first-in-human trials, with initial clinical entry targeted for 2027 He will also establish a U.S. clinical and research site to complement the company’s research capabilities in Shanghai and the U.K. SHANGHAI, LONDON & SOMERVILLE, MA, October 13, 2026 — Ailux, […]

Ailux Presents New Preclinical Data Supporting its Long-Acting IL-4Rα Antibody and Expanding its Bispecific Applications at EADV 2026

October 7, 2026 SHANGHAI, LONDON & SOMERVILLE, October 7, 2026 — Ailux, an AI-native biotech company developing next-generation biologics, today announced preclinical findings presented at the 2026 European Academy of Dermatology and Venereology (EADV) Congress. The oral presentation highlighted the company’s long-acting IL-4Rα antibody, engineered for extended half-life via pH-sensitive IL-4Rα binding. The IL-4Rα antibody […]